A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide With or Without Pomalidomide in Patients With Relapsed and Refractory Multiple Myeloma

Trial Profile

A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide With or Without Pomalidomide in Patients With Relapsed and Refractory Multiple Myeloma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Nov 2017

At a glance

  • Drugs Pomalidomide (Primary) ; Cyclophosphamide; Daratumumab; Dexamethasone
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms DCDP
  • Most Recent Events

    • 22 Nov 2017 Status changed from not yet recruiting to recruiting.
    • 28 Aug 2017 Planned End Date changed from 1 Dec 2022 to 1 Mar 2023.
    • 28 Aug 2017 Planned primary completion date changed from 1 Jul 2020 to 1 Oct 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top